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Background: Elevated plasma preprovasopressin (copeptin) levels are associated with cardiovascular complications
as well as with an increased risk for type 2 diabetes (T2D). Here, we studied, whether plasma copeptin is related to
carotid intima-media thickness (IMT), a measure of early atherosclerosis, and may thus be one explanation for the
high cardiovascular risk in T2D.
Methods: Plasma concentrations of copeptin and IMT of the common carotid artery were determined in 1275
participants of the population-based KORA F4 study. We used linear regression models to investigate associations
between copeptin levels and IMT.
Results: In the whole study group, copeptin levels were not significantly associated with IMT after adjustment for
age and sex. Copeptin and IMT were significantly inversely associated after multivariable adjustment in the total
cohort (β = -0.020 mm, 95% CI: -0.037 mm; -0.003 mm), in men (β = -0.035 mm, 95% CI: -0.061 mm; -0.009 mm) and
in study participants with prediabetes (β = -0.041 mm, 95% CI: -0.078 mm; -0.005 mm) comparing quartile 4 vs
quartile 1. The negative association of copeptin and IMT in men was present after adjustment for age alone. In
women and patients with T2D, copeptin was not significantly associated with IMT.
Conclusions: Plasma copeptin was not associated with an increased IMT in our study cohort. In contrast, copeptin
levels were related to a lower IMT in men and subjects with prediabetes, suggesting that elevated copeptin
concentrations do not exert proatherogenic effects on carotid arteries.
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The neurohormone arginine vasopressin (AVP) is secreted
from the posterior pituitary in response to osmolality,
hemodynamic changes and acute and chronic stress [1,2].
AVP targets various vasopressin receptors (VR), promot-
ing antidiuretic and antinatriuretic effects via V2R and
mediating vasoconstriction by binding to V1aR on vascu-
lar smooth muscle cells [2]. Besides these well-known* Correspondence: cornelia.then@med.uni-muenchen.de
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reproduction in any medium, provided the orfunctions, AVP has multiple metabolic effects: AVP acti-
vates release of adrenocorticotropic hormone from the
anterior hypophysis (V2R), mediates hepatic gluconeogen-
esis and glycogenolysis through V1aR and stimulates glu-
cagon and insulin secretion from pancreatic islets (V3R).
In addition, AVP exerts a complex influence on the regula-
tion of lipid metabolisms [2].
Plasma AVP is unstable and rapidly cleared from the
plasma, preventing reliable measurements. Copeptin, the
stable C-terminal part of the AVP precursor molecule, is
cleaved from pro-AVP during processing and is secreted
in an equimolar concentration with AVP. The develop-
ment of assays for copeptin determination has made it
possible to use copeptin as a reliable surrogate for AVP
measurements [3].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bolic syndrome [4,5], with an increased risk for type 2
diabetes (T2D) and with overt T2D [6,7]. Furthermore,
plasma copeptin levels are increased in heart failure [8]
and the acute coronary syndrome [9,10] in both non-
diabetic subjects and in patients with T2D [11-13]. In-
creased copeptin concentrations are related to a higher
mortality in critically ill patients and provide prognostic
implications in patients with end stage renal disease
[14], heart failure [15], myocardial infarction [16] and
stroke [17,18]. In addition, copeptin has been shown to
be associated with all-cause mortality (hazard ratio 1.22)
and cardiovascular events (hazard ratio 1.17) in diabetic
patients [19]. Thus, it may be possible that increased
plasma copeptin concentrations are involved in the de-
velopment of premature atherosclerosis.
Measurement of intima-media thickness (IMT) of the
common carotid artery by high resolution transcutaneous
ultrasound is an established non-invasive measure for the
early diagnosis of atherosclerosis and carotid plaque has
been consistently correlated with atherosclerotic vascular
lesions and with an increased risk for stroke and myocar-
dial infarction independently of traditional vascular risk
factors [20-23]. Therefore, we sought to evaluate the asso-
ciation of copeptin with IMT in a community-based
population. The association of plasma copeptin with both
cardiovascular disease [9,10] and T2D [6,7] prompted us
to stratify the study cohort according to categories of glu-
cose tolerance in order to examine a possible contribution
of elevated copeptin to the high cardiovascular risk in dia-
betes. Because previous studies have shown significant dif-
ferences in plasma copeptin values in women and men
[4,5,7,24], we also included gender-specific analyses.
Methods
Study population
The KORA (Cooperative Health Research in the Region
of Augsburg, southern Germany) F4 study is a population-
based cohort of 3080 subjects (1486 men, 1594 women)
aged 32–81 years surveyed between 2006 and 2008
(follow-up study of the KORA S4 survey conducted in
1999–2001). Standardized sampling methods and data
collection (medical history, medication, anthropomet-
ric measurements, blood pressure) have been described
in detail elsewhere [25,26]. All study participants gave
written informed consent and the study was approved
by the Ethics Committee of the Bavarian Medical Associ-
ation. IMT was measured in all study participants who
agreed to undergo ultrasound examination (n = 2663). By
study design, samples from 50% of the study participants
were randomly selected for plasma copeptin measurement
(n = 1596). All variables required for the current analyses
were available in 1275 study participants. Patients were
assigned to one of three groups (normal glucose tolerance(NGT), prediabetes or T2D) according to categories of glu-
cose tolerance. Criteria for known diabetes were a validated
physician’s diagnosis or current use of glucose-lowering
agents. After an overnight fasting period, all non-diabetic
participants underwent a standard 75 g oral glucose toler-
ance test. Newly diagnosed diabetes, impaired glucose toler-
ance, impaired fasting glucose and NGT were defined
according to the 1999 World Health Organization diagnos-
tic criteria based on both fasting and post-challenge glucose
values (≥ 7.0 mmol/l fasting or ≥ 11.1 mmol/l 2 h glucose)
[27]. Prediabetes was defined as increased fasting plasma
glucose (> 6.1 and < 7.0 mmol/l) and/or impaired glucose
tolerance (2 h glucose 7.8 - <11.1 mmol/l). Hypertension
was defined as systolic blood pressure ≥ 140 mmHg, dia-
stolic blood pressure ≥ 90 mmHg or known hypertension
with use of anti-hypertensive drugs.
Ultrasound and measurement of IMT
Ultrasound measurements of common carotid arteries
(CCA) were performed by two certified investigators as de-
scribed recently [28]. Briefly, optimal images of the right
and left CCA far wall were recorded on DVD videotapes.
IMT measurements were performed off-line over a length
of 10 mm beginning at 0–5 mm of the dilatation of the
distal CCA using an automated edge detection reading sys-
tem (Prowin software, Medical Technologies International,
USA). We used the average of the measurements of the left
and right CCA to calculate mean artery thickness of the
distal CCA. One certified reader measured all IMT scans.
Laboratory measurements
Blood was collected without stasis and was kept at 4°C
until centrifugation. All blood parameters, except for 2-h
glucose, were based on fasting blood samples. Plasma
samples were stored at −80°C until assayed and there
was only one freeze-thaw cycle before determination of
MR-proANP. Measurements of blood glucose, HbA1c,
total cholesterol, high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) cholesterol, triglycerides,
serum creatinine and high sensitive C-reactive protein
(hsCRP) were performed as described previously [29].
Glomerular filtration rate was calculated using the MDRD
equation (eGFR).
Plasma concentrations of copeptin were measured by
a validated sandwich fluoroimmunoassay (BRAHMS,
Hennigsdorf/Berlin, Germany) using the automated sys-
tem B.R.A.H.M.S KRYPTOR as described in detail else-
where [3]. The lower detection limits was 0.4 pmol/l.
Intra- and inter-assay coefficients of variation were 5.9%
and 8.9%, respectively.
Statistical analyses
Baseline characteristics were compared between subjects
with NGT, prediabetes, and T2D using F-tests in case of
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F-tests were performed on a log-scale. Logistic regres-
sion models were used to compare binomial proportions.
All comparisons were adjusted for age and sex. Spear-
man correlation coefficients were calculated between
IMT and copeptin, respectively, and conventional cardio-
vascular risk factors.
In linear regression models, the association between
quartiles of copeptin and IMT was assessed in different
models: (1) without adjustment, (2) with adjustment for
age and sex, (3) for age, sex, and body mass index
(BMI), and (4) age, sex, BMI, waist circumference (con-
tinuous), hypertension (≥ 140/90 mm Hg or antihyper-
tensive medication), HDL cholesterol (continuous), LDL
cholesterol (continuous), triglycerides (continuous), pre-
diabetes (yes/no), T2D (yes/no) former myocardial in-
farction or stroke, smoking behaviour (active/former/
never), alcohol consumption (never/moderate/high),
physical activity (high/low), hsCRP and eGFR. These
models were fitted for the whole study group, for
women and men separately, and for subjects with and
without impaired glucose metabolism. Furthermore, the
association between copeptin and IMT was determined
using copeptin as continuous variable.
As the assumptions of normally distributed residuals
and of homoscedasticity were not fulfilled when IMT
was the dependent variable in linear regression models,
we additionally used ln(IMT) as dependent variable in
linear regression models. The level of statistical signifi-
cance was set at 5%. All analyses were performed using
the SAS version 9.2 (SAS institute, Cary, NC, USA).
Results
Characteristics of the study population
Characteristics of 1275 study participants are given in
Table 1. Stratified analysis in men and women revealed
higher median crude copeptin levels in men (women: 7.5
(25th percentile 7.4; 75th percentile 13.7) pmol/l; men:
10.1 (25th percentile 7.4; 75th percentile 13.7) pmol/l;
p < 0.0001). The copeptin levels in the respective quar-
tiles are shown in Additional file 1: Table S1. There
were also sex-specific differences in crude IMT (in-
creased IMT by 0.043 ± 0.008 mm in men, p < 0.0001).
Both, copeptin and IMT were related with conven-
tional cardiovascular risk factors. Age, BMI, waist cir-
cumference, systolic and diastolic blood pressure,
triglycerides, HDL cholesterol, hsCRP and eGFR were
all related to plasma copeptin levels in the total study
cohort (Table 2). Age (r = 0.22 in men and 0.16 in women)
and declining kidney function (eGFR; r = −0.20 in men
and −0.16 in women) were significantly associated with
copeptin levels in both genders, whereas BMI (r = 0.14),
waist circumference (r = 0.13), systolic blood pressure
(r = 0.08), triglycerides (r = 0.08) and hsCRP (r = 0.18)were significantly related to copeptin only in women
(Table 2). In the total study cohort, IMT values were
significantly correlated to age, BMI, LDL cholesterol,
HDL cholesterol, triglycerides, systolic blood pressure,
waist circumference, disturbed glucose tolerance,
eGFR, and hsCRP (p < 0.0001 for all, data not shown).
Diastolic blood pressure was only slightly associated
with IMT (r = 0.05, p = 0.05).
Association of copeptin levels with IMT
Analyses of the correlations between IMT and copep-
tin were performed separately in men and women. Un-
adjusted copeptin levels were not associated with IMT
in men (r = 0.04; p = 0.312) and only weakly associated
with IMT in women (r = 0.14; p <0.001). Adjustment
for age, for age and BMI, and multiple linear regression
analyses using copeptin as independent variable resulted
in a significant inverse relation between plasma
copeptin levels and IMT in men (β = −0.035 mm, 95%
CI: -0.061 mm; -0.009 mm; Q4 vs Q1 after multivari-
able adjustment). In the fully adjusted model, IMT
was 0.038 mm (95% CI: -0.057; -0.020) lower in
copeptin quartiles 3–4 than in quartiles 1–2. In the
total cohort, copeptin and IMT were inversely associ-
ated after multivariable adjustment (β = −0.020 mm,
95% CI: -0.037 mm; -0.003 mm; Q4 vs Q1). IMT
values of subjects with copeptin in quartiles 3–4 were
0.022 mm (95% CI: -0.034; -0.010) lower than in sub-
jects in quartiles 1–2. Using copeptin as continuous
variable resulted in a significant negative relation be-
tween copeptin levels and IMT in men after multivari-
able adjustment (Table 3). In contrast, in women, no
significant association of copeptin and IMT was de-
tectable in any of the applied regression models. Ex-
clusion of study participants with former myocardial
infarction or stroke or an eGFR < 60 ml/min from the
analyses resulted in similar findings as in the entire
study cohort (Additional file 2: Table S2).
Relation of copeptin with IMT depending on glucose
homeostasis
Median levels of copeptin were higher in subjects with
T2D (10.8 (7.8; 15.2) pmol/l) compared to prediabetes
(9.1 (6.4; 12.6) pmol/l) and NGT (8.6 (5.9; 11.4) pmol/l)
(Table 1). Mean IMT was 0.082 ± 0.016 mm and 0.097 ±
0.016 mm higher in women and men with T2D as com-
pared to individuals with NGT (p < 0.0001). This associ-
ation disappeared after multivariable adjustment for
conventional cardiovascular risk factors. A significant in-
verse correlation of IMT and copeptin was apparent in
normoglycemic subjects and in study participants with
prediabetes after adjustment for age, sex and BMI and
after multivariable adjustment (Table 4). Using copeptin
as continuous variable resulted in a significant negative
Table 1 Characteristics of 1275 study participants according to categories of glucose regulation: the KORA F4 studya
All subjects NGT Prediabetes T2D pb
n 1275 911 224 140 -
Age (years) 56.6 ± 12.7 53.4 ± 12.2 63.6 ± 10.5 66.1 ± 8.6 0.001#
Sex (male) (n (%)) 624 (48.9) 419 (46.0) 120 (53.6) 85 (60.7) 0.003###
BMI (kg/m2) 27.4 ± 4.5 26.5 ± 4.2 29.4 ± 4.3 30.6 ± 4.4 0.001#
Waist (cm) 93.3 ± 13.6 90.2 ± 12.9 99.4 ± 11.9 103.9 ±11.7 0.001#
Systolic blood pressure (mm Hg) 122.1 ± 17.7 119.0 ± 16.7 128.9 ± 18.1 131.3 ± 16.7 0.001#
Diastolic blood pressure (mm Hg) 75.1 ± 9.6 74.8 ± 9.4 76.8 ± 9.9 74.7 ± 10.2 0.003#
HDL cholesterol (mmol/l) 1.47 ± 0.37 1.51 ± 0.38 1.41 ± 0.35 1.29 ± 0.29 0.001#
LDL cholesterol (mmol/l) 3.52 ± 0.88 3.49 ± 0.86 3.80 ± 0.92 3.28 ± 0.85 0.001#
Triglycerides (mmol/l) 102.0 (71.0,149.0) 93.0 (65.0; 136.0) 126.0 (93.0; 172.5) 130.5 (92.0; 206.0) 0.001##
hsCRP (mg/l) 1.10 (0.54; 2.42) 0.935 (0.46; 1.95) 1.71 (0.92; 3.40) 1.70 (0.86; 3.76) 0.001##
Estimated GFR (ml/min) 84.0 ± 18.2 85.8 ± 17.6 81.3 ± 18.2 76.8 ± 19.8 0.12#
Former stroke or MI (n (%)) 58 (4.6) 30 (3.3) 10 (4.5) 18 (12.9) 0.03###
Active or former smoker (n (%)) 728 (57.1) 534 (58.6) 110 (49.1) 84 (60.0) 0.049###
High alcohol consumption (n (%))c 249 (19.5) 179 (19.7) 42 (18.8) 28 (20.0) 0.92###
Hypertension (n (%))d 500 (39.3) 265 (29.1) 127 (56.7) 108 (77.1) 0.001###
Physically inactive (n (%))e 529 (41.5) 341 (37.4) 110 (49.1) 78 (55.7) 0.001###
Copeptin (pmol/l)
Mean ± SD 10.46 ± 16.46 9.97 ± 16.73 9.94 ± 7.20 14.5 ± 23.4 0.02##
Median (25th percentile, 75th percentile) 8.91 (6.13; 12.00) 8.59 (5.90; 11.35) 9.10 (6.42; 12.64) 10.84 (7.80; 15.16)
Intima-media-thickness (mm)
Mean ± SD 0.85 ± 0.14 0.82 ± 0.13 0.91 ± 0.14 0.92 ± 0.14 0.19##
Median (25th percentile, 75th percentile) 0.83 (0.74; 0.93) 0.80 (0.73; 0.89) 0.90 (0.80; 1.01) 0.90 (0.82; 1.02)
All analyses are adjusted for age and sex.
Abbreviations: NGT normal glucose tolerance, T2D type 2 diabetes mellitus, BMI body mass index, MI myocardial infarction, hsCRP high sensitive C-reactive
protein (serum).
aMean ± standard deviation, median (25th percentile, 75th percentile), proportions (%).
b #F-Test; ##log F-Test; ###logistic regression.
cHigh alcohol intake: ≥ 40 g/day in men, ≥ 20 g/day in women.
dSystolic blood pressure ≥ 140/90 mm Hg or antihypertensive medication.
eLess than 1 hour of physical activity per week.
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ticipants with prediabetes after adjustment for age and
sex, for age, sex and BMI and after multivariable adjust-
ment (Table 4). There was no significant association of
copeptin and IMT in patients with overt T2D.
Discussion
Inverse association of copeptin levels with IMT
The key finding of the present study is a significant in-
verse relation of copeptin plasma levels with IMT in a
community-based cohort. Our data suggest that moder-
ately increased copeptin concentrations may indicate a
reduced risk of early carotid atherosclerotic lesions in
men. Our finding is unexpected, since AVP was consid-
ered to exert mainly proatherogenic effects and previous
studies suggest a link between AVP/copeptin and the
development of vascular complications [9-11,16-18].
Copeptin has negative prognostic value for all-causemortality in severe disorders, such as heart failure
[8,30-32], coronary artery disease [33,34], acute myocar-
dial infarction [35] and stroke [17], and end-stage renal
disease [14], whereas, to our knowledge, copeptin has
not been described as a risk factor for future cardiovas-
cular events in stable patients. Plasma copeptin levels do
not reflect coronary artery status in stable patients with
coronary artery disease [36,37] or predict cardiovascular
events and incident heart failure in population-based
studies [37-39]. In line with these results our study dem-
onstrates that circulating copeptin is not an indicator for
early atherosclerosis.
What is a possible explanation for the observed in-
verse association between copeptin and IMT? AVP is
not only involved in vasoconstriction but also in nitric
oxide-mediated vasorelaxation through the binding to
the oxytocin receptor on vascular endothelium [2,40].
Experimental studies showed that AVP infusion in
Table 2 Spearman correlation coefficients (p values) between copeptin levels and cardiovascular risk factors (n = 1596)
Total sample (n = 1596) Men (n = 780) Women (n = 816)
Age 0.187 (<0.001) 0.217 (<0.001) 0.157 (<0.001)
BMI 0.106 (<0.001) −0.020 (0.57) 0.139 (<0.001)
Waist circumference 0.201 (<0.001) 0.014 (0.69) 0.126 (<0.001)
Systolic blood pressure 0.139 (<0.001) 0.014 (0.70) 0.080 (0.02)
Diastolic blood pressure 0.051 (0.04) −0.056 (0.12) 0.002 (0.94)
Triglycerides 0.094 (<0.001) −0.020 (0.58) 0.078 (0.03)
HDL cholesterol −0.135 (<0.001) 0.011 (0.75) −0.054 (0.12)
hsCRP 0.139 (<0.001) 0.115 (0.001) 0.179 (<0.001)
eGFR −0.142 (<0.001) −0.200 (<0.001) −0.156 (<0.001)
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crease, but also a V1R-mediated active vasodilatation of
carotid arteries, probably mediated by endothelial release
of nitric oxide [40], which plays an essential role in pro-
tection against vascular inflammation and endothelial
dysfunction. The net effect of circulating AVP on the
vascular bed may depend on the absolute hormone con-
centration [2]. In the present study, the median copeptin
level was 8.6-9.1 pmol/l in non-diabetic individuals,
which is comparable to levels described in other
population-based studies (ranging from 5.0 pmol/l to 8.2
pmol/l [4,6,7,41]), but 2-10-fold lower than reported in
studies investigating severe disorders, such as stroke,
myocardial infarction or end stage kidney disease
[9,14,42]. High AVP plasma concentrations predomin-
antly stimulate V1aR, mediating vasoconstriction [43]
and possibly increasing the prothrombotic potential by
platelet activation [44]. Whereas high AVP levels are
proatherogenic or indirectly indicate an increased risk
for fatal complications, intermediate AVP concentrations
may exert an inert or even protective effect on vascular
endothelium. This hypothesis needs to be confirmed in
future experimental studies.
So far, only few studies have investigated the associ-
ation between copeptin concentrations and the develop-
ment and progression of chronic atherosclerosis in the
general community. One study found elevated copeptin
concentrations to be associated with a decreased ankle-
brachial index in patients with peripheral arterial disease.
However, this association was only significant in
African-Americans, but not in non-Hispanic whites, and
all study participants had a family history of hyperten-
sion [45]. Another study described a positive association
between copeptin levels and IMT in middle-aged indi-
viduals with chronic kidney disease [46] and a further
study reported that copeptin is a predictor of stroke in
hemodialysis patients [14]. Additionally, high copeptin
levels predict microalbuminuria, an early sign of target
organ damage in diabetes and hypertension [24,47].
However, high AVP plasma levels probably promotemicroalbuminuria primarily via V2R, a pathway not ne-
cessarily connected to atherosclerotic changes. More-
over, patients with renal insufficiency differ from the
present population in several aspects. Chronic kidney
disease patients are at high risk for cardiovascular
events, often suffer from disturbances of sodium homeo-
stasis and may have an overly activated AVP system. In
addition, kidney function has a major impact on copeptin
clearance [48]. Therefore, the discrepant results may be
explained by different study population characteristics.
The effect of elevated AVP levels may depend on the
receptor subtype distribution and regulation. AVP has
been shown to exert certain pathophysiological effects in
a gender-specific manner, e.g. a higher anti-diuretic re-
sponse in females, probably due to a higher V2R density
in the collecting duct and a decreased blood and pulse
pressure sensitivity [49,50]. While, in rats, AVP induces
a stronger contraction of coronary arteries in males [51],
maximal contraction of the aorta in response to vaso-
pressin is about threefold higher in females due to a
weaker endothelium-derived nitric oxide-mediated vaso-
dilatation [52]. In addition, potentially protective vaso-
pressin effects seem to be more present in men. For
example, a V2-like receptor related vasodilator effect ex-
ists in male rats, but not in females [53]. Thus, females
seem to be less well protected against harmful vascular
AVP. This might be one explanation for the lacking rela-
tionship between copeptin and IMT in women.
Relation of copeptin with IMT depending on glucose
homeostasis
After stepwise adjustment for age and sex, for age, sex
and BMI and in the multivariate model, copeptin dis-
played significant associations with IMT only in subjects
with NGT and with disturbed glucose tolerance, but not
in patients with overt T2D. As described in previous
studies [5-7], we found an increase of plasma copeptin
in patients with T2D. Assuming that at least part of dia-
betic patients have high fasting blood glucose, the ob-
served attenuation of the relation between copeptin and
Table 3 Association of plasma copeptin levels and IMT
Copeptin Copeptin Copeptin β per 1 SD
increase in
copeptin
Q3-4 vs Q1-2 Q4 vs Q1-Q3 Q4 vs Q1
No adjustment
All subjects (N = 1,275) 0.010 0.023 0.028 0.005
(−0.005; 0.026) (0.005; 0.041) (0.006; 0.050) (−0.003; 0.013)
Men (N = 624) −0.013 0.016 0.009 0.002
(−0.036; 0.011) (−0.011; 0.043) (−0.024; 0.042) (−0.010; 0.014)
Women (N = 651) 0.032 0.030 0.046 0.008
(0.012; 0.052) (0.007; 0.053) (0.018; 0.074) (−0.002; 0.018)
Adjusted for age and sex
All subjects −0.018 −0.011 −0.015 −0.001
(−0.030; -0.006) (−0.025; 0.003) (−0.033; 0.002) (−0.007; 0.005)
Men −0.042 −0.028 −0.038 −0.009
(−0.060; -0.023) (−0.049; -0.006) (−0.064; -0.011) (−0.018; 0.001)
Women 0.005 0.004 0.006 0.005
(−0.011; 0.020) (−0.013; 0.022) (−0.016; 0.027) (−0.002; 0.013)
Adjusted for age, sex and BMI
All subjects −0.018 −0.012 −0.016 −0.002
(−0.030; -0.006) (−0.026; 0.002) (−0.033; 0.0005) (−0.008; 0.004)
Men −0.039 −0.026 −0.035 −0.009
(−0.057; -0.020) (−0.048; -0.005) (−0.061; -0.009) (−0.018; 0.0002)
Women 0.002 0.002 0.003 0.004
(−0.013; 0.018) (−0.016; 0.020) (−0.019; 0.024) (−0.003; 0.012)
Multivariable adjustmenta
All subjects −0.022 −0.014 −0.020 −0.003
(−0.034; -0.010) (−0.028; -0.0002) (−0.037; -0.003) (−0.009; 0.003)
Men −0.038 −0.024 −0.035 −0.010
(−0.057; -0.020) (−0.046; -0.002) (−0.062; -0.009) (−0.020; -0.001)
Women −0.002 −0.001 −0.001 0.004
(−0.017; 0.014) (−0.019; 0.017) (−0.023; 0.021) (−0.004; 0.012)
Gender-specific adjusted β’s (95% CI) for IMT given in mm as dependent variable and categories of copeptin as independent variable (highest quartile Q4 or Q3-4
versus lower quartiles (reference)): Results of linear regression models.
aAdjusted for: age, sex, BMI, waist (continuous), hypertension (systolic blood pressure ≥ 140/90 mm Hg or antihypertensive medication), HDL cholesterol
(continuous), LDL cholesterol (continuous), triglycerides (continuous), former myocardial infarction or stroke, smoking (active/former/never), alcohol consumption
(abstinent/moderate/high), physical activity (high/low), hsCRP, eGFR, prediabetes (yes/no), T2D (yes/no).
bold: p < 0.05.
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creased plasma osmolality followed by activation of the
AVP system. It is tempting to speculate that the osmolality-
mediated AVP/copeptin release might result in hormone
concentrations that are above the threshold value predom-
inantly mediating protective vascular effects. Alternatively,
additional risk factors may be present in diabetic patients,
overriding the potential protective effect of copeptin. It is
important to note that we observed a trend towards an in-
verse correlation between plasma copeptin and IMT also in
patients with T2D, suggesting that elevated copeptin is not
a risk factor for early carotid atherosclerosis in patients withT2D. This interpretation is in agreement with a recent pro-
spective study in diabetic patients showing that copeptin is
related to all-cause mortality but only non-significantly as-
sociated with cardiovascular events [19].
Study limitations
The major limitation of our study is its cross-sectional
design, precluding statements on causalities. Further-
more, although multivariable adjustments were per-
formed for all traditional cardiovascular risk factors and
other potentially confounding parameters, residual con-
founding cannot be excluded.
Table 4 Association of copeptin levels and IMT according to categories of glucose homeostasis
Copeptin Copeptin Copeptin β per 1 SD
increase in
copeptin
Q3-4 vs Q1-2 Q4 vs Q1-Q3 Q4 vs Q1
Total study cohort
No adjustment
NGT (n = 911) 0.007 0.019 0.024 0.001
(−0.010; 0.025) (−0.002; 0.040) (−0.001; 0.049) (−0.008; 0.010)
Prediabetes (n = 224) −0.010 −0.009 −0.024 −0.011
(−0.046; 0.027) (−0.049; 0.031) (−0.075; 0.027) (−0.055; 0.032)
T2D (n = 140) −0.018 −0.003 0.001 0.009
(−0.068; 0.032) (−0.051; 0.046) (−0.076; 0.077) (−0.006; 0.024)
Adjustment for age and sex
NGT −0.015 −0.004 −0.007 −0.004
(−0.029; -0.002) (−0.020; 0.012) (−0.026; 0.012) (−0.011; 0.002)
Prediabetes −0.028 −0.040 −0.058 −0.044
(−0.060; 0.004) (−0.075; -0.005) (−0.103; -0.014) (−0.082; -0.006)
T2D −0.025 −0.009 −0.008 0.010
(−0.071; 0.020) (−0.054; 0.035) (−0.078; 0.062) (−0.003; 0.024)
Adjusted for age, sex and BMI
NGT −0.016 −0.006 −0.008 −0.005
(−0.029; -0.003) (−0.022; 0.010) (−0.027; 0.011) (−0.012; 0.002)
Prediabetes −0.027 −0.038 −0.057 −0.042
(−0.058; 0.005) (−0.073; -0.004) (−0.101; -0.013) (−0.079; -0.004)
T2D −0.025 −0.008 −0.007 0.010
(−0.070; 0.021) (−0.053; 0.037) (−0.078; 0.063) (−0.003; 0.024)
Multivariable adjustmenta
NGT −0.018 −0.007 −0.009 −0.006
(−0.031; -0.005) (−0.023; 0.008) (−0.028; 0.010) (−0.013; 0.0002)
Prediabetes −0.031 −0.041 −0.066 −0.050
(−0.064; 0.002) (−0.078; -0.005) (−0.112; -0.019) (−0.091; -0.009)
T2D −0.030 −0.009 −0.018 0.012
(−0.081; 0.020) (−0.059; 0.040) (−0.096; 0.060) (−0.002; 0.026)
Gender-specific adjusted β’s (95% CI) according to categories of glucose tolerance for IMT as dependent variable and categories of copeptin as independent
variable (highest quartile Q4 or Q3-4 versus lower quartiles (reference)): Results of linear regression models.
aAdjusted for: age, sex, BMI, waist (continuous), hypertension (systolic blood pressure ≥ 140/90 mm Hg or antihypertensive medication), HDL cholesterol
(continuous), LDL cholesterol (continuous), triglycerides (continuous), former myocardial infarction or stroke, smoking (active/former/never), alcohol consumption
(abstinent/moderate/high), physical activity (high/low), hsCRP, eGFR.
bold: p < 0.05.
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We provide the first data on the association of copeptin
with IMT in a large population-based cohort stratified by
gender, impaired glucose tolerance and T2D. We found
an inverse association of copeptin and IMT, suggesting
that moderately increased copeptin concentrations are re-
lated to a lower degree of atherosclerotic alterations in the
CCA. Thus, plasma copeptin does not seem to be an inde-
pendent risk factor for early carotid atherosclerosis in the
general population. Whether slightly increased copeptin
concentrations may be protective from macrovascularcomplications needs to be investigated in a prospective
epidemiological study.
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